Click on image to view larger version.

Figure 1 The coronary flow reserve (CFR) (left) and fractional flow reserve (FFR) (right) responses to abciximab and percutaneous transluminal coronary angioplasty (PTCA). Abciximab improved CFR but not FFR, indicating a greater effect of the drug on coronary microvascular function than on stenosis severity. Data are shown as average values ± SEM. *p < 0.05 vs. baseline. °p < 0.01 vs. baseline and abciximab.